Ads for ineffective drugs reel in the dollars

2019-03-02 02:11:00

SPIRALLING healthcare costs will be a big issue in the US presidential election. So here’s a number for the candidates to debate: $1.5 billion. That’s the additional sum spent on cholesterol-lowering drugs in the US in 2006, thanks to the marketing of a drug that has not been shown to reduce the risk of cardiovascular disease. Cynthia Jackevicius of the Western University of Health Sciences in Pomona, California, and colleagues analysed US and Canadian prescriptions of ezetimibe, a drug that inhibits the uptake of cholesterol. Ezetimibe was launched in the US as Zetia in 2002,